Requirement of Metabolic Activation for Estrogenic Activity of Pueraria mirifica

Lee, Y.-S.;Park, J.-S.;Cho, S.-D.;Son, J.-K.;Cherdshewasart, W.;Kang, Kyung-Sun

  • Published : 20020000


A wide range of chemicals derived from plant and human-made xenobiotics are reported to have hormonal activities. The present study was performed to examine the estrogenic effect of Kwao Keur, Pueraria mirifica (PM), that has been used as a rejuvenating folk medicine in Thailand. using recombinant yeast, MCF-7 cell proliferation and HepG2 cell transient transfection assay. In recombinant yeast assay, 0.025, 0.25, 2.5, 25, $2.5{\times}10^2$ $2.5{\times}10^3$, $2.5{\times}10^4$mg/mI concentrations of PM did not show any estrogenic activities, while $10^{-9}$ of 17 ${\beta}$-estradiol (positive control) showed high estrogenic activity. Estrogenic activities were induced at 2.5ng/mI to 25${\mu}g$ml concentrations of PM in a dose-dependent manner on MCF-7 cells and the estrogenic effect of PM was blocked by tamoxifen treatment, a well-known anti-estrogen, PM also showed estrogenic effect on human hepatoma cell line, HepG2 cells, containing estrogen receptor and luciferase reporter gene. Taken together, PM in itself may have no estrogtenicity in yeast system, but it has estrogenicity in MCF-7 & HepG2 cells that have human metabolic enzymes. The results indicated that PM may require metabolic activation for estrogenic activity.


pueraria mirifica (PM);endocrine disrupter;metabolic activation


  1. Bulger W.H., Muccitelli R.M., and Kupfer D., Studies on the in vivo and in vitro estrogenic activities of methoxychlor and its metabolites; role of hepatic monooxygenase in methoxychlor activation. Biochem. Pharmacol. 1978, 28, 2417-2423.
  2. Makela S., Davis V.L., Tally W.C., Korkman J., Salo L., Vihko R., Santti R., Korach K.S., Dietary estrogens act through estrogen receptor-mediated processes and show no antiestrogenicity in cultured breast cancer cells. Environ Health Perspect 1994, 102, 572-581.
  3. Messina M.J., Persky V., Setchell KDR, Barnes S., Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994, 21, 113-131.
  4. Odum J., Lefevre P.A., Tittensor S., Paton D., Routledge E.J., Beresford N.A., Sumpter J.P. and Ashby J., The rodent uterotrophic assay: critical protocol features, studies with nonyl phenols, and comparison with a yeast estrogenicity assay. Regul. Toxicol. Pharmacol. 1997, 25, 176-188.
  5. Shelby M.D., Newbold R.R., Tully D.B., Chae K., Davis V.L., Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays, Environ Health Perspect 1996, 104(12):1296-1300.
  6. Kuiper G.G., Carlesson B., Grandien K., Enmark E., Haggblad J., Nilsson S., and Gustafsson J-A, Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors and ${\beta}$. Endocrinology 1997, 183, 863-870.
  7. Markiewicz L, Garey J., Adlercreutz H., Gurpide E., In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol BioI 1993, 45, 399-405.
  8. Tremblay G.B., Tremblay A., Copeland N.G., Gilbert D.J., Jenkins N.A., Labrie F. and Giguere V., Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor ${\beta}$. Mol Endocrinol 1997, 11, 353-365.
  9. Iafrati M.D.., Karas R.H., Aronovitz M., Kim S., Sullivan T.R., Lubahn D.B., O'Donnell T.F., Korach K.S., Mendelsohn M.E., Estrogen inhibits the vascular injury response in estrogen receptor deficient mice. Nature Med 1997, 3, 545-548.
  10. Kuiper G.G., Lemmen J.G., Carlsson B.O., Corton J.C., Safe S.H., van der Saag P.T., van der Burg B., and Gustafsson J-A, Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor. Endocrinology 1998, 139, 4252-4263.
  11. Mosselman S., Polman J., and Dijkema R., Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996, 392, 49-53.
  12. Chansakaow S., Ishikawa T., Seki H, Sekine K., Okada M, and Chaichantipyuth C., Identification of deoxymiroestrol as the actual rejuvenating principle of "Kwao Keur". Pueraria mirifica. The known miroestrol may be an artifact. J. Nat. Prod., 2000, 63(2), 173-175.
  13. Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y. and Shine Y., Sequence and expression of human estrogen receptor complementary DNA,. Science, 1986, 231, 1150-1154.
  14. Chansakaow S., Ishikawa T., Sekine K., Okada M., Higuchi Y., Kudo M., Chaichantipyuth C, Isoflavonoids from Pueraria mirifica and their estrogenic activity. Planta Med 2000, 66(6), 572-575.
  15. Korach K.S., Migliaccio S., Davis V.L., Estrogen, In:Munson PL (ed) Principles of Pharmacology-Basic Concepts and Clinical Applications. Chapman and Hall New York 1994, 809-825.
  16. Farhat M.Y., Lavigne M.C., Ramwell P.W., The vascular protective effects of estrogen. FASEB J 1996, 10, 615-624.
  17. Breithofer A., Graumann K., Scicchitano M.S., Karathanasis S.K., Butt T.R., Jungbauer A., Regulation of Human Estrogen receptor by phytoestrogens in Yeast and Human Cells. J. Steroid. Biochem. Mol. BioI. 1998, 67(5-6), 421-429.
  18. Miksicek R.J., Commonly occurring plant flavonoids have estrogenic activity. :Mol Fharmacol 1993, 44, 37-43.
  19. Kuiper G.G., Enmark E., Pelto-huikko M., Nilsson S. and Gustafsson J-A, Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93, 5925-5930.
  20. Turner R.T., Riggs B.L., Spelsberg T.C., Skeletal effects of estrogens. Endocr Rev 1994, 15, 275-300.